Compare ELDN & TKNO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ELDN | TKNO |
|---|---|---|
| Founded | 2004 | 1996 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Medicinal Chemicals and Botanical Products |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 291.8M | 268.1M |
| IPO Year | 2014 | 2021 |
| Metric | ELDN | TKNO |
|---|---|---|
| Price | $3.60 | $7.27 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 2 | 0 |
| Target Price | ★ $8.50 | N/A |
| AVG Volume (30 Days) | ★ 932.7K | 223.8K |
| Earning Date | 05-12-2026 | 05-06-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 30.67 | ★ 43.86 |
| EPS | N/A | ★ N/A |
| Revenue | N/A | ★ $40,520,000.00 |
| Revenue This Year | N/A | $8.27 |
| Revenue Next Year | N/A | $13.13 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 7.35 |
| 52 Week Low | $1.35 | $1.91 |
| 52 Week High | $4.60 | $7.84 |
| Indicator | ELDN | TKNO |
|---|---|---|
| Relative Strength Index (RSI) | 48.09 | 68.56 |
| Support Level | $3.31 | $4.87 |
| Resistance Level | $3.96 | N/A |
| Average True Range (ATR) | 0.17 | 0.62 |
| MACD | 0.01 | 0.10 |
| Stochastic Oscillator | 56.00 | 79.03 |
Eledon Pharmaceuticals Inc is a clinical stage biotechnology company using immunology expertise in targeting the CD40 Ligand pathway to develop therapies to protect transplanted organs and prevent rejection, and to treat amyotrophic lateral sclerosis. Its compound in development is tegoprubart, an IgG1, anti-CD40L antibody with high affinity for the CD40L, a well-validated biological target that has broad therapeutic potential. It operates as one reportable segment, focused on the development of tegoprubart, to develop therapies to protect transplanted organs and prevent rejection, and to treat ALS.
Alpha Teknova Inc is a producer of critical reagents for the discovery, development, and commercialization of novel therapies, vaccines, and molecular diagnostics. Its offer two primary product categories: Lab Essentials and Clinical Solutions. It derives key revenue from the United States. The company offers three primary product types: (i) pre-poured media plates for cell growth and cloning; (ii) liquid microbial culture media and supplements for cellular expansion; and (iii) molecular biology reagents for sample manipulation, resuspension, and purification.